<html><head><meta content="text/html; charset=UTF-8" http-equiv="content-type"><style type="text/css">ol{margin:0;padding:0}table td,table th{padding:0}.c0{color:#000000;font-weight:400;text-decoration:none;vertical-align:baseline;font-size:12pt;font-family:"Times New Roman";font-style:normal}.c1{padding-top:0pt;padding-bottom:0pt;line-height:2.0;orphans:2;widows:2;text-align:left}.c3{background-color:#ffffff;max-width:468pt;padding:72pt 72pt 72pt 72pt}.c2{height:11pt}.title{padding-top:0pt;color:#000000;font-size:26pt;padding-bottom:3pt;font-family:"Arial";line-height:1.15;page-break-after:avoid;orphans:2;widows:2;text-align:left}.subtitle{padding-top:0pt;color:#666666;font-size:15pt;padding-bottom:16pt;font-family:"Arial";line-height:1.15;page-break-after:avoid;orphans:2;widows:2;text-align:left}li{color:#000000;font-size:11pt;font-family:"Arial"}p{margin:0;color:#000000;font-size:11pt;font-family:"Arial"}h1{padding-top:20pt;color:#000000;font-size:20pt;padding-bottom:6pt;font-family:"Arial";line-height:1.15;page-break-after:avoid;orphans:2;widows:2;text-align:left}h2{padding-top:18pt;color:#000000;font-size:16pt;padding-bottom:6pt;font-family:"Arial";line-height:1.15;page-break-after:avoid;orphans:2;widows:2;text-align:left}h3{padding-top:16pt;color:#434343;font-size:14pt;padding-bottom:4pt;font-family:"Arial";line-height:1.15;page-break-after:avoid;orphans:2;widows:2;text-align:left}h4{padding-top:14pt;color:#666666;font-size:12pt;padding-bottom:4pt;font-family:"Arial";line-height:1.15;page-break-after:avoid;orphans:2;widows:2;text-align:left}h5{padding-top:12pt;color:#666666;font-size:11pt;padding-bottom:4pt;font-family:"Arial";line-height:1.15;page-break-after:avoid;orphans:2;widows:2;text-align:left}h6{padding-top:12pt;color:#666666;font-size:11pt;padding-bottom:4pt;font-family:"Arial";line-height:1.15;page-break-after:avoid;font-style:italic;orphans:2;widows:2;text-align:left}</style></head><body class="c3 doc-content"><p class="c1"><span class="c0">Central Intelligence Agency (CIA)</span></p><p class="c1"><span class="c0">Office of Intelligence Analysis</span></p><p class="c1"><span class="c0">Date: July 27, 2024</span></p><p class="c1 c2"><span class="c0"></span></p><p class="c1"><span class="c0">Confidential Intelligence Report</span></p><p class="c1"><span class="c0">Subject: Riley Clos</span></p><p class="c1"><span class="c0">Case Number: 2024-CIA-4471</span></p><p class="c1"><span class="c0">Charge: To create, distribute, or dispense, or possess with intent to distribute or dispense, a counterfeit substance</span></p><p class="c1 c2"><span class="c0"></span></p><p class="c1"><span class="c0">1. Background</span></p><p class="c1"><span class="c0">Name: Riley Clos</span></p><p class="c1"><span class="c0">Date of Birth: May 27th, 2008</span></p><p class="c1"><span class="c0">Place of Birth: Shakopee, Minnesota, USA</span></p><p class="c1"><span class="c0">Current Residence: [redacted]</span></p><p class="c1"><span class="c0">Occupation: Greeter at [redacted]</span></p><p class="c1"><span class="c0">Affiliations: Underground 49th</span></p><p class="c1 c2"><span class="c0"></span></p><p class="c1"><span class="c0">Summary: Riley Clos has come under scrutiny following allegations related to the creation, distribution, and possession with intent to distribute counterfeit substances. The case stems from a series of investigations initiated by local law enforcement and federal agencies that have identified potential links to illegal activities involving counterfeit drugs.</span></p><p class="c1 c2"><span class="c0"></span></p><p class="c1"><span class="c0">2. Allegations and Evidence</span></p><p class="c1"><span class="c0">A. Allegations:</span></p><p class="c1 c2"><span class="c0"></span></p><p class="c1"><span class="c0">Creation of Counterfeit Substances: Riley Clos is alleged to have manufactured counterfeit substances intended to mimic controlled drugs.</span></p><p class="c1"><span class="c0">Distribution: It is reported that Clos has engaged in activities aimed at distributing these counterfeit substances.</span></p><p class="c1"><span class="c0">Possession with Intent to Distribute: Evidence suggests that Clos was found in possession of large quantities of these substances, indicating potential distribution efforts.</span></p><p class="c1"><span class="c0">B. Evidence:</span></p><p class="c1 c2"><span class="c0"></span></p><p class="c1"><span class="c0">Physical Evidence: A search warrant executed on Clos&#39;s residence on July 10, 2024, uncovered several counterfeit drug pills and powders, along with equipment used for their production. Analysis of these substances revealed they were not genuine controlled substances but were designed to imitate them.</span></p><p class="c1"><span class="c0">Digital Evidence: Digital forensics of Clos&rsquo;s electronic devices uncovered communications and transactions indicating a network of buyers and distributors involved in the counterfeit drug market.</span></p><p class="c1"><span class="c0">Witness Testimonies: Several individuals with knowledge of Clos&rsquo;s activities have provided testimony that suggests Clos has been involved in the creation and distribution of counterfeit substances.</span></p><p class="c1"><span class="c0">3. Operational Intelligence</span></p><p class="c1"><span class="c0">A. Connections and Network:</span></p><p class="c1 c2"><span class="c0"></span></p><p class="c1"><span class="c0">Local Network: Clos appears to have connections with individuals involved in the local drug market, particularly those seeking counterfeit substances.</span></p><p class="c1"><span class="c0">Online Presence: Clos has used online platforms to market and sell these counterfeit substances, leveraging digital anonymity to facilitate transactions.</span></p><p class="c1"><span class="c0">B. Risk Assessment:</span></p><p class="c1 c2"><span class="c0"></span></p><p class="c1"><span class="c0">Public Safety Risk: The distribution of counterfeit substances poses a significant risk to public health and safety, as these substances may be mistaken for legitimate drugs and can lead to harmful consequences.</span></p><p class="c1"><span class="c0">Operational Threat: Clos&#39;s operations have demonstrated an understanding of how to evade law enforcement detection, making this case a priority for continued surveillance and investigation.</span></p><p class="c1"><span class="c0">4. Recommendations</span></p><p class="c1"><span class="c0">Enhanced Surveillance: Continue monitoring Clos&rsquo;s activities and communications to gather further evidence and identify additional associates or suppliers involved in the counterfeit drug network.</span></p><p class="c1"><span class="c0">Collaborate with Local Authorities: Work closely with local law enforcement to support ongoing investigations and enforcement actions against Clos and his network.</span></p><p class="c1"><span class="c0">Public Awareness Campaign: Consider a public awareness campaign to educate about the dangers of counterfeit substances and to potentially solicit information from the public.</span></p><p class="c1"><span class="c0">5. Conclusion</span></p><p class="c1"><span class="c0">Riley Clos is currently under investigation for serious charges related to the creation, distribution, and possession of counterfeit substances. The evidence collected thus far indicates a substantial operation involving counterfeit drugs, with potential links to broader illegal networks. Continued surveillance and coordinated efforts with local authorities are essential to address this threat effectively.</span></p><p class="c1 c2"><span class="c0"></span></p><p class="c1"><span class="c0">Report Prepared By:</span></p><p class="c1"><span class="c0">Traci Hunter Abramson</span></p><p class="c1"><span class="c0">Position: Intelligence Analyst</span></p><p class="c1"><span class="c0">Agency: Central Intelligence Agency (CIA)</span></p><p class="c1 c2"><span class="c0"></span></p><p class="c1"><span class="c0">End of Report</span></p></body></html>